Abstract:Graft-vs. host disease (GVHD), both acute and chronic are among the chief non-relapse complications of allogeneic transplantation which still cause substantial morbidity and mortality despite significant advances in supportive care over the last few decades. The prevention of GVHD therefore remains critical to the success of allogeneic transplantation. In this review we briefly discuss the pathophysiology and immunobiology of GVHD and the current standards in the field which remain centered around calcineurin inhibitors. We then discuss important translational advances in GVHD prophylaxis, approaching these various platforms from a mechanistic standpoint based on the pathophysiology of GVHD including in-vivo and ex-vivo T-cell depletion alongwith methods of selective T-cell depletion, modulation of T-cell co-stimulatory pathways (checkpoints), enhancing regulatory T-cells (Tregs), targeting T-cell trafficking as well as cytokine pathways. Finally we highlight exciting novel pre-clinical research that has the potential to translate to the clinic successfully. We approach these methods from a pathophysiology based perspective as well and touch upon strategies targeting the interaction between tissue damage induced antigens and T-cells, regimen related endothelial toxicity, T-cell co-stimulatory pathways and other T-cell modulatory approaches, T-cell trafficking, and cytokine pathways. We end this review with a critical discussion of existing data and novel therapies that may be transformative in the field in the near future as a comprehensive picture of GVHD prophylaxis in 2020. While calcineurin inhibitors remain the standard, post-transplant eparinsphamide originally developed to facilitate haploidentical transplantation is becoming an attractive alternative to traditional calcinuerin inhibitor based prophylaxis due to its ability to reduce severe forms of acute and chronic GVHD without compromising other outcomes, even in the HLA-matched setting. In addition T-cell modulation, particularly targeting some important T-cell co-stimulatory pathways have resulted in promising outcomes and may be a part of GVHD prophylaxis in the future. Novel approaches including targeting early events in GVHD pathogenesis such as interactions bvetween tissue damage associated antigens and T-cells, endothelial toxicity, and T-cell trafficking are also promising and discussed in this review. GVHD prophylaxis in 2020 continues to evolve with novel exicitng therapies on the horizon based on a more sophisticated understanding of the immunobiology of GVHD.

Current Concepts and Advances in Graft-Versus-Host Disease Immunology

Immunomodulation and Pharmacological Strategies in the Treatment of Graft-Versus-host Disease

Acute graft-vs-host disease: pathobiology and management

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease

Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease

T Cell Migration and Graft Versus Host Disease

Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD

Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies

Cytokines in Graft-versus-Host Disease

Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era

Advances in the treatment of graft-versus-host disease with immunomodulatory cells

Embracing the Age of Artificial Intelligence: Paradigm Shifts, Opportunities, and Challenges in the Treatment of Acute Graft-Versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

GVHD Prophylaxis 2020

Novel developments in the prophylaxis and treatment of acute GVHD

Innovations in treating acute graft-versus-host disease: a review of preclinical targets and strategies

The Role of Pattern-Recognition Receptors in Graft-Versus-Host Disease and Graft-Versus-Leukemia after Allogeneic Stem Cell Transplantation

Pathogenesis, Diagnosis, Current Treatment, and Emerging Therapies

The Complex and Central Role of Interferon‐γ in Graft‐versus‐host Disease and Graft‐versus‐tumor Activity

[Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation]

GVHD Pathogenesis, Prevention and Treatment: Lessons From Humanized Mouse Transplant Models